Reach Us +44-1522-440391
Glycemic Control With Intensive Insulin Treatment Is Fundamental To Renal Preservation In Diabetes | 4330
ISSN: 2161-0959

Journal of Nephrology & Therapeutics
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Glycemic control with intensive insulin treatment is fundamental to renal preservation in diabetes

International Conference and Exhibition on Nephrology & Therapeutics

Anil K. Mandal and Linda M Hiebert

ScientificTracks Abstracts: J Nephrol Therapeut

DOI: 10.4172/2161-0959.S1.004

Volume 2 Issue 5 - 27 International Conference and Exhibition on Nephrology & Therapeutics August 20-22, 2012 Hilton Chicago/Northbrook, USA J Nephrol Therapeut ISSN: 2161-0959 JNT, an open access journal Nephro-2012 August 20-22, 2012 Objective: Diabetic nephropathy is the most common cause of chronic kidney disease (CKD), which progresses to end stage renal disease (ESRD) requiring dialysis. We ask if CKD progression is preventable by glycemic control with intensive insulin treatment. Methods: Data was obtained from 46 office treated patients (28F, 18 M) with established diabetes. Mean age was 62.2 (range 39 � 86 years. They were followed for a mean period of 14.2 (1.5 � 115) months. Diabetes was diagnosed by 2-h postprandial glucose (2hPPG) of > 11.1 mmol/L and treated with Glargine or detemir insulin after breakfast and dinner and regular insulin based on finger-stick glucose reading 2-h post meal and bedtime. Hypertension was treated with therapy with complete exclusion of renin- angiotensin inhibitor drugs. Glucose, urea nitrogen, serum creatinine (Scr), estimated glomerular filtration rate (eGFR), and glycosylated hemoglobin (HbA1c), and blood pressure (BP) were recorded. Values were compared between first and last visits using a paired two-tailed t-test. P< 0.05 was significant. Patients were divided by 2hPPG of < or > 11.1 mmol/L. Results: In the all patients group, fasting glucose was significantly lower at the last versus the first visit (8.4 � 0.6 vs. 10.3 � 0.7 mmol/L, p=0.0173), and was associated with a significantly reduced Scr (100.3 + 5.2 vs. 110.9 + 7.8 μmol/L, p=0.0134). Little change in eGFR was found between visits. Mean eGFR was no worse than CKD stage 1 in all groups at the last visit. Less than 50% of 46 patients achieved glucose control of <11.1 mmol/L, with a highly significant reduction of HbA1c (9.14 � 0.52 vs. 7.60 � 0.45%, p=0.0148). Average BPs were normal in both visits in all groups, but diastolic BP was significantly lower in the all patients group at the last visit (77.7 � 1.5 vs. 81.6 � 1.9 mmHg, p=0.0297). Conclusion: Thus the paradigm of therapy in this study may not be affirmative in uniformly achieving tight glycemic control (< 11.1 mmol/L) but is proven to be effective in renal preservation over time in diabetes

Dr. Mandal is a native of India and a naturalized citizen of the United States. He is board certified in Internal Medicine and Nephrology (kidney disease and hypertension). He is an author of 13 books and more than 250 published articles and abstracts on research in diabetes and kidney disease. He is a two-times Fulbright Scholar and a visiting professor in 23 countries that invited him to lecture on diabetes, high blood pressure, and kidney diseases.